⌕
Sarepta Therapeutics · SRPT · Nasdaq
Tenet 48 · Mixed
Compare
$14.77−2.38%At closeTenet 48 · Mixed
$14.77−0.36 (−2.38%)
At close: Nov 17, 2026, 4:00 PM ET· Nasdaq · USD

Sarepta Therapeutics (SRPT) Earnings Forecast

Analysts expect Sarepta Therapeutics (SRPT) to earn $2.59 a share in FY26, the average of 10 estimates as of Nov 16, 2026.

Sources Analyst estimates EstimatesConsensus as of How we compute thisNot investment advice

4 figures withheld by our checks. Each blank figure names its reason.

FY26 consensus EPS
$2.59
10 analysts
FY27 consensus EPS
$0.15
11 analysts · low $0.03, high $0.30
EPS revisions, 31 days
−17.4%
$3.14 to $2.59
Disagreement, FY26
61.0%
high to low, $1.90 to $3.48

Consensus estimates only. Analysts' price forecasts and ratings are not licensed here.

Consensus as of Nov 16, 2026 · we check it nightly

Analysts expect Sarepta Therapeutics to lose $0.35 a share in FY30; 3 analysts publish an estimate for FY30.

Forward P/E · FY26E
5.8×
$15.13 (as of close, Nov 16, 2026) ÷ $2.59 consensus EPS
Coverage · FY26
10 · 16
EPS estimates · revenue estimates

Are estimates going up or down lately?

The FY26 EPS consensus is $2.59, down 25.2% in 90 days. Every figure compares one fiscal period at both ends.

EPS consensus, change over the last 90 days. One step per nightly change.

−95.6%−39.5%+16.5%FY26 −25.2%FY27 −80.8%Aug 18Nov 16
EPS30 days90 daysshown aboveSince Jul 6
FY2610 analysts▼ −17.4%$3.14 to $2.59▼ −25.2%$3.46 to $2.59▼ −29.6%$3.68 to $2.59
FY2711 analysts▼ −71.1%$0.51 to $0.15▼ −80.8%$0.76 to $0.15▼ −85.3%$1.00 to $0.15
Dec '268 analysts▼ −1212.5%$−0.03 to $−0.35▼ −425.1%$0.11 to $−0.35▼ −425.1%$0.11 to $−0.35
Mar '274 analysts24 of 30 days−503.3% so far24 of 90 days−503.3% so far▼ −503.3%$0.01 to $−0.05

Contributors at both ends of the window: FY26 11 and 10. A change in the average can come from a new contributor as much as from a changed mind, so both counts stay in view.

Measured between two of our own nightly snapshots of one fiscal period, so a new fiscal year entering the view is never read as a revision. Never backfilled. A window still filling says how many days it holds; a blank one means our record is not that long yet.

If the Street is right, what does that imply for the share price?

Price as of close, Nov 16, 2026 · consensus as of Nov 16, 2026

At 55.8 times earnings, its average over the last five fiscal years, the FY27 consensus of $0.15 works out to $8 a share.

Consensus EPS · FY27
$0.15
11 analysts · low $0.03, high $0.30 · thin coverage
Multiple · five-year average P/E
55.8×
Average of the fiscal-year P/Es, FY24 to FY24.
×
Receipt · SRPT · FY27Nov 16, 2026
Implied, a share
$8

Range on the low and high estimate: $2 to $17.

$2 low$17 high
0.15 × 55.8, to the dollar
Drag the multipleShaded: where Sarepta Therapeutics' P/E sat at each fiscal year end, FY24 to FY24. Each dot is one year.
50×52×54×56×58×60×
5-yr avg 55.8×10-yr median 55.8×$8 a share

Each point on the line is a multiple, and the flag is the price it implies for FY27. Past multiples are context, not a guide to future ones.

This is multiplication, not a forecast. It assumes the market pays the multiple you chose and that the consensus is right. Both are often wrong.

You are paying 5.8 times the FY26 consensus for earnings the Street expects to shrink about 96% a year to FY28. A falling number is not a growth rate, so the multiple is not divided by it here.

How much do analysts disagree?

For FY30, estimates run from $−0.41 to $−0.28 around an average of $−0.35, drawn by 3 analysts.

FY26E10 analysts
$1.90 to $3.48 · $1.58 wide
FY27E11 analysts
$0.03 to $0.30 · $0.26 wide
FY28E9 analysts
$−0.02 to $0.05 · $0.07 wide
FY29E3 analysts
$−0.39 to $−0.26 · $0.13 wide
FY30E3 analysts
$−0.41 to $−0.28 · $0.14 wide

The dashed line is FY25 filed $−7.13, on the GAAP basis.

A wide spread is disagreement, not risk; a narrow one is agreement, not accuracy. Later years are always wider because fewer people forecast them. Bars in amber rest on fewer than 15 analysts. The tick on each bar is the average. Spreads are shown in currency rather than as percentages, because a percentage of a number near zero overstates it.

Is next quarter a high bar or an easy one?

Analysts expect Sarepta Therapeutics to lose $0.35 a share in the December quarter, the average of 8 estimates. Results are expected by Feb 1, 2027. Last quarter, which ended in March, Sarepta Therapeutics earned $2.88 a share. Analysts had expected $0.98, so it came in 195.1% higher.

0
$−2.62
$−0.35high $1.15
low $−1.89
Dec 2025 quarterfiled · GAAPDec 2026 quarterconsensus · Street basis · 8 analysts
Expected report
Feb 1, 2027
Expected by Feb 1. An estimate, not a date the company has set. Companies move it.
Revenue expected · December quarter
$354.2M
13 analysts, 327.8 to 390.2 in $M · 442.9 in the same quarter a year ago

A year ago this quarter was a loss, so the change from it is not a percentage and none is printed. Last quarter's comparison is measured against the last estimate we hold for that quarter rather than the one from the night before the report, because the nearest estimate we hold for it was recorded after the company had already reported. For the March quarter, analysts expect a loss of $0.05 a share.

Does Sarepta Therapeutics usually beat or miss?

So far we have checked 2 quarters, of which 2 came in above the estimate we held. We add a quarter to this record each time Sarepta Therapeutics reports. The next report is expected by Feb 1, 2027.

We started recording estimates on Jul 6, 2026, so quarters that reported before that date cannot be checked.

Before our record
Dec '23
Our record, one quarter per report
Mar '24left out · basis
Jun '24left out
Sep '24left out
Dec '24left out · adjusted
Mar '25left out · adjusted
+127.1%
Jun '25reaction
+19.5%
Sep '25left out
Dec '25left out · adjusted
+195.1%
Mar '26reaction
−9.7%
Jun '26left out · adjusted
Sep '26left out · adjusted
reportsFeb 1
Dec '26
Checked so far
2 quarters
one more every report
Beat expectations
2 of 2
full details on the Earnings tab
Share price reaction
Not held
we hold no measured reaction for the quarters we have checked
Typical gap vs estimate
Not yet
shown once 4 quarters are checked

Checked against the company's reported figure (GAAP) and the average estimate we recorded the night before its results release. Where analysts' number is on an adjusted basis, we leave the comparison out rather than force it. We started recording estimates for Sarepta Therapeutics on Jul 6, 2026, so earlier quarters cannot be checked, and we never fill them in after the fact. Jun '25, Mar '26 are drawn hollow: we hold no estimate for those quarters recorded strictly before the report, so it is scored against the last estimate we hold rather than the night-before one.

The Street expects sales to grow −24.5% in FY27 and EPS −94.3%. The net margin moves from 15.1% to 1.2%, and the implied share count from about 109M to 118M, so these numbers assume no buyback.Show the decomposition and the margin ladderHide the decomposition
FY27 EPS growth, in points
Revenue growth−24.5
Net margin change−69.3
Share count change−0.5
EPS growth−94.3
Legs are rounded to a tenth of a point and the largest remainder carries the difference, so they add to the total. Implied shares = consensus net income ÷ consensus EPS, a direction rather than a decimal.
10 analysts publish an EPS estimate for FY26 and 16 publish revenue. Coverage thins with distance: 3 EPS estimates for FY30. Consensus figures are on the Street's basis and filed figures are GAAP; we label the gap, we do not explain it away.Show coverage by year and over timeHide the coverage chart
Analysts by fiscal year · outlined revenue, filled EPS. Amber marks a panel of fewer than 15.
1610
FY26E
1611
FY27E
139
FY28E
113
FY29E
63
FY30E
The FY26 panel held 12 analysts when our record of it began on Jul 6, 2026 and holds 10 tonight.

The full consensus, year by year

Consensus as of Nov 16, 2026 · filed figures as reported
Revenue · $Bfiled · consensus average · band = low to high
0.81.52.2historyStreet forecastFY22FY25FY30E

Coverage thins with distance: 16 revenue estimates for FY26, 6 for FY30.

Diluted EPS · $filed · consensus average · band = low to high
−8.72−2.393.94historyStreet forecastFY22FY25FY30E

Out-year bands widen as fewer analysts publish: 10 EPS estimates for FY26, 3 for FY30.

Fiscal yearRevenue $BYoYEPS $YoYEBITDA $BNet inc. $BShares BAnalysts rev · EPSFwd P/E
FY25Filed2.2—−7.13————as filedn/m
FY26E1.91.8 to 1.9▼15.2%a2.591.90 to 3.48n/ca0.40.30.1116 · 105.8×
FY27E1.41.2 to 1.6▼24.5%0.150.03 to 0.30▼94.3%0.10.00.1216 · 11103.0×
FY28E1.40.9 to 1.7▼3.5%0.01−0.02 to 0.05▼96.5%0.10.00.3613 · 92,978.9×
FY29E1.21.0 to 1.4▼8.9%−0.34−0.39 to −0.26n/cb0.0−0.00.1011 · 3—
FY30E1.21.0 to 1.3n/cb−0.35−0.41 to −0.28—0.0−0.00.106 · 3—

Average estimate with low to high beneath. Amber counts mark thin coverage and thin rows carry an amber rule. Shares = consensus net income ÷ consensus EPS, a direction rather than a decimal. The filed row's last column is today's price over that year's filed EPS, the one trailing multiple in that column. a This step crosses the seam: last year is a filed GAAP actual and this year is a consensus estimate, so the two are not prepared on one basis. b More than a third of the analyst panel changed between these two years, so the difference of the two averages measures the panel rather than the forecast.

These are consensus estimates: what analysts expect the business to earn, not where they think the stock trades. Coverage thins and the low to high band widens in the out-years. Context, not advice.

Analysts' price forecasts and grades are not licensed here. This page shows forward consensus estimates only: 10 EPS estimates for FY26, 16 for revenue. Not investment advice.

What do analysts expect Sarepta Therapeutics to earn in FY26?

Analysts expect Sarepta Therapeutics to earn $2.59 a share in FY26, the average of 10 estimates as of Nov 16, 2026.

What is Sarepta Therapeutics' earnings forecast for FY27?

The FY27 consensus for Sarepta Therapeutics is $0.15 a share from 11 analysts, with a low of $0.03 and a high of $0.30, as of Nov 16, 2026.

Have analysts raised Sarepta Therapeutics' earnings estimates?

Sarepta Therapeutics' FY26 EPS consensus fell 25.2% in 90 days, from $3.46 to $2.59, as of Nov 16, 2026.

Install Tenet on your phone

Tenet home pageMethodology© 2026 Tenet Investing Inc.

Data from Intrinio and Financial Modeling Prep.